Otsuka’s Novel Samska Gets Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency concerned about change in sodium level as basis for approval of hyponatremia drug.
You may also be interested in...
Defining Efficacy Without Proof Of Benefit: FDA Panel To Assess Otsuka’s Samska
Cardio-Renal Advisory Committee meets June 25 to review tolvaptan’s effect on serum sodium in hyponatremia.
Defining Efficacy Without Proof Of Benefit: FDA Panel To Assess Otsuka’s Samska
Cardio-Renal Advisory Committee meets June 25 to review tolvaptan’s effect on serum sodium in hyponatremia.
FDA Accepts NDA For Otsuka’s Novel Hyponatremia Treatment
Tolvaptan could be the first oral vasopressin receptor antagonist on the market.